Product information and disease descriptionProduct descriptionProduct information
Product comparison
22 evidence topics · 16 sources
Absence of head-to-head trials: company statement on cross-study comparisons
Barzolvolimab: phase 3 dosing regimens and planned BLA submission
Barzolvolimab: subcutaneous pre-filled syringe and potential self-administration at home
Barzolvolimab: Week 12 UAS7 change and UAS7=0 in EMBARQ-CSU1 and EMBARQ-CSU2
| Arm | EMBARQ-CSU1 LS mean change (SE) in UAS7 at Week 12 | EMBARQ-CSU2 LS mean change (SE) in UAS7 at Week 12 | EMBARQ-CSU1 UAS7=0 at Week 12 | EMBARQ-CSU2 UAS7=0 at Week 12 |
|---|---|---|---|---|
| Placebo | “-10.7 (0.65)” | “-11.4 (0.64)” | “9.3%” | “12.6%” |
| Barzolvolimab 150 mg every 4 weeks | “-20.2 (0.64)” | “-20.2 (0.63)” | “42.4%” | “45.7%” |
| Barzolvolimab 300 mg every 8 weeks | “-20.5 (0.65)” | “-19.7 (0.64)” | “42.1%” | “44.0%” |
Omalizumab: CSU indication, subcutaneous dosing every 4 weeks, and administration setting
Omalizumab: anaphylaxis boxed warning
Omalizumab: UAS7=0 at Week 12 in CSU Trial 1
Dupilumab: CSU indication and subcutaneous dosing every 2 weeks in adults
Dupilumab: CUPID Study A and Study C results at Week 24, and Study B
| Outcome at Week 24 | CUPID Study A dupilumab (N=68) | CUPID Study A placebo (N=68) | CUPID Study C dupilumab (N=73) | CUPID Study C placebo (N=75) |
|---|---|---|---|---|
| LS mean change (SE) in UAS7 | “-20.99 (1.77)” | “-11.95 (1.81)” | “-15.61 (2.62)” | “-11.27 (2.61)” |
| UAS7 ≤6, n (%) | “32 (47.1)” | “16 (23.5)” | “29 (39.7)” | “17 (22.7)” |
| UAS7 = 0, n (%) | “22 (32.4)” | “9 (13.2)” | “22 (30.1)” | “13 (17.3)” |
Remibrutinib: CSU indication in adults and oral dosing twice daily
Remibrutinib: UAS7 change, UAS7 ≤6, and UAS7 = 0 at Week 12 in REMIX-1 and REMIX-2
| Outcome at Week 12 | REMIX-1 remibrutinib (N = 309) | REMIX-1 placebo (N = 153) | REMIX-2 remibrutinib (N = 297) | REMIX-2 placebo (N = 153) |
|---|---|---|---|---|
| LS mean (SE) change in UAS7 | “-20.02 (0.72)” | “-13.79 (0.98)” | “-19.41 (0.70)” | “-11.73 (0.95)” |
| UAS7 ≤6, n (%) | “154 (49.8)” | “38 (24.8)” | “139 (46.8)” | “30 (19.6)” |
| UAS7 = 0, n (%) | “96 (31.1)” | “16 (10.5)” | “83 (27.9)” | “10 (6.5)” |
Draft joint task force guideline: direct and retail prices of omalizumab, dupilumab, and remibrutinib as of December 2025
| Medication | Example packages | Direct price | Retail price |
|---|---|---|---|
| Omalizumab | “1 syringe/pen per box” | “$1475 per month” | “$1,525.61 per 150mg” |
| Dupilumab | “Carton” | “$4,193.03 per carton” | “$3100.84-5132.09 per carton” |
| Remibrutinib | “60 tablets” | “$4,424.01 per bottle” | “$4,521 per bottle” |
International guideline: dupilumab effect relative to omalizumab, oral remibrutinib, and cost restrictions
“Results of Phase 3 studies show the efficacy of dupilumab as add‐on treatment, which is however, likely to be less pronounced than those observed with omalizumab” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In September 2025 remibrutinib was approved by the FDA as an oral treatment for adult patients with CSU who remain symptomatic despite H1‐antihistamine treatment and does not require injections or lab monitoring” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“but it is acknowledged that omalizumab, dupilumab, and remibrutinib have restrictions due to their high cost” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis for the joint task force guideline: omalizumab and remibrutinib among the most effective
Network meta-analysis of biologic and targeted synthetic treatments for antihistamine-refractory CSU
“Most biological and synthetic target‐specific drugs for antihistamine‐refractory chronic spontaneous urticaria (CSU) have not been compared head‐to‐head.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“23 randomized clinical trials with 6933 participants that compared 26 different interventions or dosages and placebos were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Omalizumab 300 mg [MD −10.07, 95% CI (−11.35; −8.82)] continues to demonstrate superior efficacy compared with placebo. Remibrutinib, at doses of 35 mg once daily [MD −7.80, 95% CI (−12.76; −2.51)], 25 mg twice daily [MD −7.69, 95% CI (−9.85; −5.76)], and 10 mg twice daily [MD −7.61, 95% CI (−12.59; −2.47)], had the best overall performance for efficacy and safety. Dupilumab, fenebrutinib, and rilzabrutinib also showed greater efficacy than placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant differences were found among all treatment comparisons for AEs and SAEs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis of omalizumab, dupilumab, and remibrutinib at Weeks 12 and 24
“Urticaria Activity Score (UAS7), Itch Severity Score (ISS7), Dermatology Life Quality Index (DLQI; DLQI 0/1), disease control (UAS7 ≤ 6), and symptom remission (UAS7 = 0) were assessed at weeks 12/24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Fifteen studies (4,913 patients) were included. Omalizumab 300 mg demonstrated the greatest efficacy in UAS7, ISS7, symptom remission, and disease control at both timepoints. Remibrutinib showed the greatest DLQI improvement and second-highest UAS7 reduction and odds of symptom remission. Dupilumab provided sustained itch relief but delayed efficacy. Lower omalizumab doses lacked durability at 24 weeks.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Time to minimal clinically important difference in UAS7 across approved and investigational therapies
“This study aims to provide indirect evidence on the relative time to meaningful clinical response across approved and investigational therapies using a Bayesian network meta-analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary outcome was the mean time in weeks to minimal clinically important difference (MCID), defined as a UAS7 reduction of 10 points.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Only omalizumab 300 mg every 4 weeks, dupilumab 300 mg every 2 weeks, and ligelizumab 72 mg and 120 mg every 4 weeks achieved statistically significant reductions compared with placebo. All treatments had wide credible intervals reflecting limited direct comparisons.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Matching-adjusted indirect comparison of omalizumab versus dupilumab at Week 12
“Pooled patient-level data from the omalizumab ASTERIA I/II trials ( NCT01287117 /01292473) were compared with published aggregate data from the dupilumab LIBERTY-CSU CUPID Study A trial” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Improvements in both disease activity and itch severity were statistically significantly greater for omalizumab versus dupilumab (least squares mean [95% confidence interval] difference: UAS7, −7.6 [−13.0, −2.2], P = .006; ISS7, −3.0 [−5.8, −0.3], P = .031).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Change from baseline in UAS7 at week 12 for omalizumab versus placebo was −12.6 (−15.7, −9.5) and for dupilumab versus placebo was −5.0 (−9.3, −0.7).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote